2Q26 demand improves for CROs and pharma services, but the credit view remains selectively cautious

Overview

This report reviews the 2Q26 results and credit investment views for IQVIA, Fortrea, and Avantor. All three companies indicated improving funding conditions and end-market demand and raised FY26 revenue guidance. The report takes a constructive view of improving industry demand, but the credit recommendations have not broadly turned positive: IQVIA remains Neutral due to its strong competitive position, robust free cash flow, and stable leverage; although Fortrea is improving, it remains a "show-me story" with high leverage, warranting an Underweight rating; Avantor delivered stronger results, but BMP has not yet returned to growth, resulting in differentiated credit views across security classes.

Core views

The core view is that demand in the CRO and pharma services sectors is improving, supported particularly by emerging biopharma financing, RFP volumes, outsourcing trends, and new drug launch activity; however, credit investors still need to differentiate among issuers and levels of the capital structure. IQVIA has the most resilient fundamentals, but current valuations offer limited upside and its Commercial business may face AI disruption; Fortrea's improvement is not yet sufficient to offset high leverage and refinancing uncertainty; Avantor is benefiting from deleveraging and positive free cash flow, but BMP growth still needs to be validated.

Analysis framework

The report applies a credit research framework, combining 2Q26 revenue, EBITDA, free cash flow, orders, backlog, book-to-bill, leverage, liquidity, changes in FY26 guidance, and management commentary on demand and financing conditions to assess each issuer's credit trends and relative value.

Methodology notes

• Credit researchJ.P. Morgan Credit Research bond-level rating system

  Overweight, Neutral, Underweight

  Ratings incorporate relative valuation and fundamental credit views, focusing on cash flow debt-servicing capacity, leverage, interest coverage, liquidity, profitability, and asset quality; Neutral indicates an expected risk position over the next three months broadly in line with the relevant index, sector, or benchmark, while Underweight indicates expected underperformance.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• IQVIA Holdings Inc / IQV.US

  CRO and commercialization services provider; the report maintains a Neutral credit view.

  Strengths

  Strong competitive position and an important service provider to EBP customers; strong free cash flow, stable leverage, and ample liquidity; RFP volumes and new-order growth indicate healthy demand.

  Weaknesses

  The Commercial business may be affected by AI disruption, and the expected tailwind still requires validation; current credit levels offer limited upside.

  Comparison

  Compared with CRO peers, IQVIA derives more revenue from EBP, which is an important source of clinical trial innovation and outsourcing demand.

  Risks

  Leveraged acquisitions, AI disruption, and weakening pharmaceutical, EBP, or biotech financing conditions.

• Fortrea Holdings Inc / FTRE.US

  CRO issuer; the report maintains an Underweight credit view.

  Strengths

  2Q26 results exceeded J.P. Morgan's and market expectations; new-business wins and backlog diversification improved; improving macro and financing conditions make positive free cash flow expectations for 2H26 and FY26 more realistic.

  Weaknesses

  It remains a "show-me story"; 1L leverage is high at 7.5x; no indication of future debt redemption has yet been provided.

  Comparison

  In line with the industry, Fortrea is also seeing improved biotech financing and faster RFP flow into the pipeline, but the quality of the fundamental improvement still requires validation over additional quarters.

  Risks

  Upside risks include stronger new orders, market-share gains, and proactive debt repayment; rating risks include early refinancing, M&A, and a stronger-than-expected improvement in results.

• Avantor / AVTR

  Pharma services and laboratory products issuer; the term loan remains Neutral and unsecureds remain Underweight.

  Strengths

  2Q26 revenue and EBITDA were stronger than expected; VWR returned to growth; ample free cash flow was used for debt repayment, supporting deleveraging.

  Weaknesses

  BMP has not yet returned to growth and has not generated growth year to date; performance consistency is insufficient and current price compensation is inadequate.

  Comparison

  Compared with IQVIA and Fortrea, Avantor's credit story depends more on business-segment recovery and cash-flow deleveraging than on pure CRO order improvement.

  Risks

  M&A, accelerated deleveraging, asset sales, and BMP failing to return to growth as expected in 2H26.

Key data

• IQVIA 2Q26 revenue$4.4bn, up 8.7% year over yearOverall results were broadly in line with expectations, and revenue growth was consistent with improving demand.
• IQVIA 2Q26 EBITDA$994mm, EBITDA margin 22.8%EBITDA margin expanded 30bp year over year.
• IQVIA new orders$3.15bn, book-to-bill 1.2xNew orders grew 19% year over year, with strong full-service bookings.
• IQVIA FY26 revenue guidance$17.275bn-$17.475bnRevenue guidance was raised, implying approximately 6.5% growth at the midpoint.
• IQVIA leverage and liquidity4.1x gross leverage, 3.6x net leverage, $1.9bn cash, $2bn RCFLeverage was stable sequentially and liquidity was ample.
• Emerging biopharma financing2Q26 EBP funding $35bnThe amount was more than double 2Q25 levels and was highlighted by IQVIA management as a key market demand driver.
• Fortrea 2Q26 backlog$7.8bnThe cancellation rate remained within the historical normal range, and backlog burn was 8.6%.
• Fortrea leverage1L leverage 7.5xHigh leverage is a key reason for maintaining the Underweight rating.
• Fortrea FY26 revenue guidance$2.62bn-$2.69bnRaised from the previous range of $2.55bn-$2.65bn.
• Fortrea FY26 EBITDA guidance$205mm-$220mmRaised from the previous range of $190mm-$200mm.
• Avantor 2Q26 FCF$141mmApproximately $112mm was used for debt repayment, supporting the deleveraging commitment.
• Avantor net leverage3.4x as of 2026-06-30The company's target is net leverage below 3x.
• Avantor VWR revenue$1,240.5mm, up 1.7% year over yearVWR returned to growth in 2Q26 after bottoming in 1Q26.
• Avantor BMP revenue$451.8mm, down 5.1% year over yearAffected by comparisons in Serum, Electronic Materials, and Fluid Handling.
• Avantor FY26 organic revenue growth guidance(0.5%)-0.5%Raised from the previous range of (2.5%)-(0.5%), reflecting 2Q26 performance and improved expectations for VWR growth in the second half.
• Avantor FY26 FCF guidance$500mm-$550mmFree cash flow guidance was unchanged.

Impact & implications

The implication for credit investment is that improving industry demand can support revenue and orders, but does not automatically justify a broadly bullish stance. IQVIA is better suited to a neutral allocation, with attention to the medium- and long-term impact of AI on its Commercial business; Fortrea needs to demonstrate the quality of its improvement through sustained orders, free cash flow, and deleveraging; Avantor's credit improvement depends on whether VWR growth continues, BMP returns to growth in 2H26, and cash debt repayment remains sustainable.

Risks

• AI may disrupt analytics and consulting revenue within IQVIA's Commercial business.
• A deterioration in pharmaceutical, emerging biopharma, or biotech financing conditions could affect CRO orders and outsourcing demand.
• Fortrea's leverage remains high; if free cash flow or refinancing progress falls short of expectations, credit pressure could persist.
• Avantor's BMP segment remains in decline; failure to return to growth in 2H26 would weaken the recovery thesis.
• Potential M&A could increase leverage or alter capital-allocation priorities.
• Current prices for certain bonds or loans may not adequately compensate for fundamental uncertainty.

What to watch

• Further quantification from IQVIA management of AI's impact in 2027 and beyond.
• Whether EBP financing levels, RFP volumes, and CRO order conversion rates remain sustained.
• Whether IQVIA can deliver its FY26 revenue and EBITDA guidance, particularly the contribution from organic growth.
• Whether Fortrea proceeds with refinancing its TLA, TLB, or A/R facility, and whether terms improve.
• Whether Fortrea's 2H26 free cash flow turns positive and supports actual deleveraging.
• Whether Avantor's VWR growth continues and BMP returns to growth in 2H26.
• Whether Avantor continues to use free cash flow for debt repayment and reduces net leverage below 3x.